{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Innoviva, Inc."},"Symbol":{"label":"Symbol","value":"INVA"},"Address":{"label":"Address","value":"1350 OLD BAYSHORE HIGHWAY,SUITE 400, BURLINGAME, California, 94010, United States"},"Phone":{"label":"Phone","value":"+1 650 238-9600"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline."},"CompanyUrl":{"label":"Company Url","value":"https://www.inva.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Pavel Raifeld","title":"Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}